Graves' Disease with Thymic Hyperplasia: The Response of the Thyroid Function, Thyrotropin Receptor Autoantibody, and Thymic Size to Thiamazole Treatment
-
- Tsukada Daichi
- Department of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan
-
- Iizuka Katsumi
- Department of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan Department of Clinical Nutrition, Fujita Health University, Japan Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institution, Japan
-
- Takao Ken
- Department of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan
-
- Liu Yanyan
- Department of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan
-
- Kubota Sodai
- Department of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institution, Japan
-
- Okamoto-Kubota Saki
- Department of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institution, Japan
-
- Sakurai Teruaki
- Department of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan
-
- Imaizumi Toshinori
- Department of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan
-
- Sakai Mayu
- Department of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan
-
- Kato Takehiro
- Department of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan
-
- Mizuno Masami
- Department of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan
-
- Hirota Takuo
- Department of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan
-
- Suwa Tetsuya
- Department of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan
-
- Horikawa Yukio
- Department of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan
-
- Yamamoto Mayumi
- Health Administration Center, Gifu University, Japan
-
- Kubota Sumihisa
- Kubota Thyroid Clinic, Japan
-
- Yabe Daisuke
- Department of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institution, Japan Division of Molecular and Metabolic Medicine, Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine, Japan Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Japan
Search this article
Abstract
<p>We treated a 22-year-old woman suffering from Graves' disease and thymic hyperplasia. She was referred to our institution for a close investigation of thyrotoxicosis and thymic mass. Thyroid tests and magnetic resonance imaging resulted in a diagnosis of Graves' disease and thymic hyperplasia. The thyroid function and thyroid-stimulating hormone receptor antibody (TRAb) were normalized one and five months after thiamazole initiation, respectively. The thymic size began to decrease after 1 month and was further decreased after 5 months; it was normalized after 12 months. The correlation between TRAb titers and the thymic size (R2=0.99) suggested that the patient's autoimmunity might have contributed to the thymic hyperplasia. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 61 (18), 2753-2757, 2022-09-15
The Japanese Society of Internal Medicine